CENTRESTAGE Brings Together Global Brands to Showcase Inclusion and Diversity
14.9.2022 16:45:00 EEST | Business Wire | Press release
CENTRESTAGE 2022, one of Asia’s most anticipated annual fashion events, will be held from 9 to 11 September at the Hong Kong Convention and Exhibition Centre (HKCEC) Halls 1A-C. More than 240 fashion brands and designer labels from 15 countries and regions will take part in the three-day fashion presentation, promoting a wide variety of ready-to-wear apparel and accessories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220904005055/en/
CENTRESTAGE Asia's Fashion Spotlight (Photo: Business Wire)
This year’s CENTRESTAGE revolves around the theme of “Inclusion and Diversity”, inviting visitors to express themselves boldly through fashion and at the same time, celebrating the differences between bodies, cultures and ideologies.
CENTRESTAGE will host more than 30 fashion events in these three days, including a series of brand shows and seminars. The opening gala show on 9 September at 7pm, CENTRESTAGE ELITES, will see the global launch of the latest collections from two designer brands – Derek Chan and Mite Chan’s renowned brand DEMO from Hong Kong, as well as acclaimed Japanese designer Hideaki Shikama’s Children of the discordance. Both Derek Chan and Hideaki Shikama were chosen as the 10 Asian Designer to Watch in 2020 by Fashion Asia Hong Kong. Watch the show live on CENTRESTAGE’s website.
CENTRESTAGE will again be open to public and trade visitors throughout the entire show period, providing an ideal platform for visitors to share the joys of fashion and shopping. A wide array of interactive experiences empowered by AR and VR technologies will be offered at the fairground to enrich visitors’ experience, including the brand new CENTREVERSE, a custom-built metaverse where visitors can interact and participate in fashion events using personalised avatars.
These are just among some of the highlights to look forward to at this year’s CENTRESTAGE. Register now for free admission or visit the event’s official website for more information.
CENTRESTAGE Elites opening gala show
Date: 9 September (Fri)
Time: 7:00-7:30pm
Live-stream: https://bit.ly/3wtFEVS
CENTRESTAGE 2022
Date: 9-11 September (Fri to Sun)
Venue: Hong Kong Convention and Exhibition Centre, Halls 1A-C
Register now for free: https://bit.ly/3CAAJqh
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220904005055/en/
Contact information
Media Enquiries
Please contact the HKTDC's Exhibitions Department:
Sum Luk
Tel: (852) 2240 4048
Email: cs.luk@hktdc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom